Despite Global Restructuring Plan, It’s Full Steam Ahead In China For Merck
This article was originally published in PharmAsia News
Executive Summary
Days after announcing a global restructuring plan, Merck CEO Ken Frazier visits Beijing to pledge $6 million toward the second phase of C-MAP, a public-private partnership with the Chinese government on HIV/AIDS. Frazier’s trip underscores the continuing importance of China to Merck despite a company-wide plan to cut 8,500 positions and reduce operating costs by $2.5 billion by 2015.
You may also be interested in...
Merck’s Big Move: Massive Cost Cuts And R&D Changes Ahead
Merck will cut 8,500 positions and reduce operating costs by $2.5 billion by 2015 to jumpstart growth in the midst of slowing sales and several late-stage pipeline setbacks. A key initiative is to recharge R&D by reinvesting in key projects and increasing business development activities.
First Spring Sign: Chinese Vaccines Maker Gets $290m Funding
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.
Podcast: Biopharma's Moment To Deliver On Coronavirus And The People's Hope
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
Need a specific report? 1000+ reports available
Buy Reports